A long-acting formulation of the investigational integrase inhibitor cabotegravir (CAB) is being studied as a single agent for HIV prevention. (CAB also has been studied, in combination with long-acting rilpivirine, as treatment for people with HIV, see Long-Acting Injectable ART: Cabotegravir + Rilpivirine; this combination has been submitted for FDA approval).
In July 2020, the U.S. Food and Drug Administration approved fostemsavir (FTR) for treatment of people with multi-drug resistant HIV-1 whose current ARV regimen is failing because of resistance, intolerance, or safety issues. FTR is a novel attachment inhibitor that binds the HIV envelope glycoprotein gp120 and blocks HIV attachment to the CD4 receptor. It is given orally, 600 mg twice daily.
Recommendations and Reports / July 24, 2020 / 69(6);1–8
Exposure to hepatitis viruses is a recognized occupational risk for health care personnel (HCP). This report establishes new U.S. Centers for Disease Control and Prevention (CDC) guidance that includes recommendations for a testing algorithm and clinical management for health care personnel with potential occupational exposure to hepatitis C virus (HCV).
Over the past few years, numerous studies have examined weight gain in people with HIV who start or change antiretroviral therapy (ART). While it is clear that some people gain excessive amounts of weight after starting (and sometimes upon changing) ART, the roles of specific antiretroviral (ARV) agents or classes are not entirely clear, nor the mechanisms responsible. Emerging data have been incomplete and contradictory, but concern has been particularly focused on the effects of integrase inhibitors (INSTIs) and of tenofovir alafenamide (TAF).
In 2018, initial results from the Tsepamo study of birth outcomes in Botswanan women treated with ART during pregnancy raised questions about the safety of dolutegravir (DTG) when given at the time of conception or very early in pregnancy. Specifically, an early interim analysis found a higher proportion of neural tube defects (NTDs) in infants born to women who were taking DTG at the time of conception (0.94%) compared with women taking ART regimens that did not include DTG (0.12%).
As the global battle to understand and eliminate the coronavirus continues, a new study published in the Journal of Dental Research demonstrates that testing of oropharyngeal secretions (OS) may reduce the number of false-negative results from nasal swab testing of patients who have seemingly recovered from the disease.
Below is the preliminary schedule of AETC Program sessions and poster presentations planned for the 2020 National Ryan White Conference on HIV Care & Treatment. The AETC National Coordinating Resource Center will also be exhibiting, representing the AETC Program's training materials, services, and clinical resources. This page will be updated as new information becomes available. Please continue to check back for updates and for the complete schedule.
The US Centers for Disease Control and Prevention issued updated interim infection prevention and control guidance for dental settings during the COVID-19 response on May 19, 2020, very similar to science-based guidance issued earlier in May by the American Dental Association (ADA).
I never thought my experience as a Black woman, nor my experience as a woman who enjoys sex, would combine in a way that could put me in jail. When I was diagnosed with HIV in 2003, I had a very limited understanding of what that meant with respect to accessing treatment, being virally suppressed, dating, disclosure, fear... living. I would wait until my family finished eating, washing clothes and dishes for the day before I would wash and clean for myself. This is no way to live while managing an illness.